News

Sonoma Biotherapeutics Raises $265M

August 05, 2021
Biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and type 1 diabetes.

Epygenix Therapeutics to Proceed With Trial for the Treatment of Dravet Syndrome

August 03, 2021
Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy that uses UCSF technology developed by Dr. Scott Baraban, is pleased to announce that the company's ARGUS trial with EPX-100 (Clemizole Hydrochloride) in patients with Dravet syndrome...

RxSight sets terms for $125 million IPO

July 27, 2021
RxSight, a commercial med-tech company based on UCSF post-cataract intraocular lens technology, announced terms for its IPO on Monday. The company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18.  MORE

Erasca Announces Closing of Initial Public Offering

July 21, 2021
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes...

Device taps brain waves to help paralyzed man communicate

July 14, 2021
University of California, San Francisco, neurosurgeon Dr. Edward Chang performs surgery at UCSF. In a medical first, researchers, led by Chang, harnessed the brain waves of a man paralyzed and unable to speak for 15 years - and turned what he intended to say into sentences on a computer screen. ...

Erasca to be valued at up to $1.8 billion

July 13, 2021
Erasca Inc. disclosed that it has set terms of its initial public offering, in which the California-based pre-revenue, clinical-stage precision oncology company could be valued up to $1.84 billion. University of California's researcher, Kevan Shokat PhD., is a lead contributor to Erasca's cancer...

UCSF and PrinterPrezz Collaborate to Produce a Layer of Personal Protection

July 01, 2021
Dr. Alessandro Villa, an Associate Professor at UC San Francisco, and PrinterPrezz, a trailblazer in combining polymer and metal 3D printing, nanotechnologies and surgical expertise to design and manufacture next generation medical devices, today announced a partnership to produce “The Cupola,” a...

The Next Pandemic?

June 30, 2021
Even with powerful vaccines in hand and the coronavirus waning across most of the United States, there’s still an urgent need for drugs to treat COVID-19 — and that could lay the foundation for the next generation of therapies for pandemics, say Bay Area scientists conducting such research. MORE

Sana Biotechnology Shows Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates

June 28, 2021
First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression. Transplanting allogeneic cells into a primate without immune suppression represents a key step toward widespread treatment of disease using...

Akili launches digital campaign for first FDA-approved ADHD video game

June 28, 2021
Akili’s newly launched treatment for ADHD is a prescription—but not a drug. It's a video game. And the company is taking a fittingly digital approach to launching the first-of-its-kind FDA-approved product. MORE

Pages